Shares of Danaher cratered 14.2% to $172.57 on July 21 after the life-sciences conglomerate delivered a second quarter that topped Wall Street estimates on both the top and bottom line — then quietly narrowed its full-year revenue growth outlook. The result: a classic "beat and guide-down" selloff that signals investors are deeply worried about the speed of Danaher's recovery.
The Numbers Looked Good Until You Read the Fine Print. Revenue hit $6.27 billion, beating estimates of $6.1 billion by 2.7%, while adjusted EPS of $1.94 topped the $1.85 consensus by 4.9%.
Danaher raised full-year adjusted EPS guidance to $8.45–$8.60 and narrowed its core revenue growth forecast to 3.0%–4.0%. That matters because the prior range was 3%–6% — lopping off two full points from the top end tells Wall Street that management no longer sees a path to the best-case scenario.
Biotech Was the Weak Spot Investors Feared Most. The Biotechnology segment posted Q2 sales of $1.92 billion , falling short of the $1.95 billion consensus, which had assumed 5.5% growth.
Management attributed the shortfall to customer project timing in its bioprocessing business, though order trends remained strong. Bioprocessing — which sells equipment and consumables to drug manufacturers — is the business investors watch most closely as a barometer of broader pharma spending. A miss there, even a modest one, feeds the narrative that the post-pandemic recovery in biotech demand is slower than expected.
A Soft Q3 Outlook Sealed the Selloff. The third-quarter core revenue growth guide of just 2.0%–3.0% appeared to disappoint investors, driving the sharp decline.
High-growth markets expanded roughly 15% and now make up about 31% of sales, but developed markets were flat to slightly down, with softness in Europe and North America. That geographic split raises a strategic question: how dependent is the recovery on China, and how sustainable is that?
The $9.9 Billion Masimo Bet Adds Complexity. Danaher completed its acquisition of Masimo, a patient-monitoring company, on June 10 , adding to an already-heavy debt load. The company ended 2025 with $15.1 billion in net debt , and management expects Masimo to contribute only $0.15–$0.20 to EPS in its first full year. Investors are effectively being asked to finance a pricey diversification into hospital bedside monitors while the core biotech franchise is still sputtering — a tough ask at any valuation, let alone one that still traded above 23× forward earnings before today's drop.